Business & Finance
PharmaJet signs manufacturing agreement with Enzychem Lifesciences to supply COVID-19 vaccine to several lower-middle income countries in Latin America and Asia
5 January 2022 -

Injection technology company PharmaJet said on Tuesday that its partner Zydus Cadila has announced an agreement with Korea's Enzychem Lifesciences to manufacture the COVID-19 plasmid DNA vaccine (ZyCoV-D) in Korea.

Zydus Cadila's ZyCoV-D vaccine was recently granted emergency use approval (EUA) by India's national regulatory agency for those aged 12 years and above.

Under the terms of the agreement, the vaccine will be manufactured in Korea and exported to several lower-middle income countries in Latin America and Asian New Southern Policy member countries.

Pursuant to the agreement, Zydus will transfer its manufacturing technology and provide technical assistance to Enzychem Lifesciences.

The ZyCoV-D covid-19 vaccine is reportedly administered intradermally using the PharmaJet needle-free system, which can be deployed more readily, especially in resource-poor populations where these are urgently needed.